
<oai_dc:dc xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
  <dc:title>Results of Prolonged Treatment with Pentolinium Tartrate with Special Reference to the Addition of Rauwolfia, Hydralazine or Both</dc:title>
  <dc:subject>Hypertension</dc:subject>
  <dc:subject>Antihypertensive Agents</dc:subject>
  <dc:subject>Rauwolfia</dc:subject>
  <dc:subject>Hydralazine</dc:subject>
  <dc:subject>Pentolinium Tartrate</dc:subject>
  <dc:description>Freis and Wilson reported in this article on the use of the pentolinium tartrate in severely hypertensive patients. They noted that a combination of the ganglionic-blocking agent, Rauwolfia (a tropical plant whose root was commonly used in herbal treatments), and the vasodilator hydralazine provided the greatest reduction in blood pressure with the fewest side effects.</dc:description>
  <dc:publisher>American Heart Association, June 1956</dc:publisher>
  <dc:publisher>The American Heart Association, June 1956</dc:publisher>
  <dc:contributor>Circulation</dc:contributor>
  <dc:contributor>Freis, Edward D.</dc:contributor>
  <dc:contributor>Wilson, Ilse M.</dc:contributor>
  <dc:type>Articles</dc:type>
  <dc:format>Archival Materials</dc:format>
  <dc:format>Text</dc:format>
  <dc:format>10 pages</dc:format>
  <dc:identifier>nlm:nlmuid-101584929X124-doc</dc:identifier>
  <dc:identifier>101584929X124</dc:identifier>
  <dc:identifier>http://resource.nlm.nih.gov/101584929X124</dc:identifier>
  <dc:identifier>Profiles ID: XFBBHZ</dc:identifier>
  <dc:language>English</dc:language>
  <dc:relation>Profiles in Science</dc:relation>
</oai_dc:dc>